Key result
Cardiac pacemaker implantation in patients with symptomatic bradycardia improved mean MMSE scores by 2 points (p<0.001) and decreased IL-1β by 8.6 pg/mL (p=0.049) at 42 days.
Why the study?
Bradyarrhythmias cause low cerebral blood flow with secondary neuronal ischemia and cognitive dysfunction, prompting evaluation of the effect of cardiac pacemaker implantation on cognitive function and inflammatory markers.
Does cardiac pacemaker implantation improve cognitive function and inflammatory markers in patients with symptomatic bradyarrhythmias?
Population
31 patients with symptomatic bradyarrhythmias
Comparison
Before vs after cardiac pacemaker implantation
Design
Prospective observational study
Follow-up
Average period of 42 days
Authors
Loading...
Pacemaker implantation may enhance cognition in symptomatic bradyarrhythmias; leaves open causal confirmation in randomized trials.
Observational (n=31)
Does cardiac pacemaker implantation improve cognitive function and inflammatory markers in patients with symptomatic bradyarrhythmias?
Mean Difference: 2
p-value: p=<0.001
Cardiac pacemaker implantation in patients with symptomatic bradycardia is associated with improved cognitive function, increased cardiac output, and decreased systemic inflammation (IL-1β).
Marțiș et al. (2021) conducted an observational in Symptomatic bradyarrhythmias (n=31). Cardiac pacemaker implantation vs. Baseline (before pacemaker implantation) was evaluated on Cognitive function (Mini-Mental State Examination score) (MD 2 points, p=<0.001). Cardiac pacemaker implantation in patients with symptomatic bradycardia improved mean MMSE scores by 2 points (p<0.001) and decreased IL-1β by 8.6 pg/mL (p=0.049) at 42 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: